Press Releases
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Hallador Energy Company (“Hallador” or the “Company”) (NASDAQ: HNRG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Groupon, Inc. (“Groupon” or the “Company”) (NASDAQ: GRPN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. (“Semler” or the “Company”) (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
The new venture fuses storytelling and social commerce, where creators build IP and brands help shape the plot.
Via ACCESS Newswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Coinbase Global, Inc. (“Coinbase” or the “Company”) (NASDAQ: COIN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. (“Caleres” or the “Company”) (NYSE: CAL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tesla, Inc. (“Tesla” or the “Company”) (NASDAQ: TSLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reddit, Inc. (“Reddit” or the “Company”) (NYSE: RDDT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit is pending against Rocket Companies, Inc. (“Rocket Companies” or the “Company”) (NYSE: RKT). Investors in Rocket Companies securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eos Energy Enterprises, Inc. (“Eos” or the “Company”) (NASDAQ: EOSE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Digimarc Corporation (“Digimarc” or the “Company”) (NASDAQ: DMRC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of United Natural Foods, Inc. (“United Natural” or the “Company”) (NYSE: UNFI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Luminar Technologies, Inc. (“Luminar” or the “Company”) (NASDAQ: LAZR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Meta Platforms, Inc. (“Meta” or the “Company”) (NASDAQ: META). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EchoStar Corporation (“EchoStar” or the “Company”) (NASDAQ: SATS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Photronics, Inc. (“Photronics” or the “Company”) (NASDAQ: PLAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Broadmark Realty Capital Inc. (“Broadmark” or the “Company”) (NYSE: BRMK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Boeing Company (“Boeing” or the “Company”) (NYSE: BA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
DELRAY BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Sunwave Health, a leading provider of healthcare software solutions, today announced the recent release of its MARA UR (Utilization Review), which was unveiled on April 28 at the company’s annual user summit. With the click of a button, the time required to prepare concurrent reviews for insurance authorization requests is significantly reduced, while still delivering the comprehensive and accurate information needed to secure additional patient care. Previously, Utilization Review Specialists (URS) spent significant time gathering the necessary information before their call with the insurance provider. With MARA, the information is compiled instantly, allowing the URS to quickly review, adjust, or add details, prior to proceeding with the authorization review call. This time-saving innovation boosts productivity and allows for more direct patient care.
By Sunwave Health · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Laser Photonics Corporation (“Laser Photonics” or the “Company”) (NASDAQ: LASE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy (“Strategy” or the “Company”) (NASDAQ: MSTR) and certain officers. The class action, filed in the United States District Court for the Eastern District of Virginia, and docketed under 25-cv-00861, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Strategy securities between April 30, 2024 and April 4, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. (“DoubleVerify” or the “Company”)(NYSE: DV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Designer Brands Inc. (“Designer Brands” or the “Company”) (NYSE: DBI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
VSiN Continues Expansion of its Leading Sports Radio Network with Addition of Top 25 Market
By VSiN · Via GlobeNewswire · July 1, 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
ERGO Group AG (“ERGO”) today announced the successful completion of the full acquisition of NEXT Insurance by Munich Re Group. Consequently, NEXT Insurance is now embedded within the management structure of ERGO, the major primary insurance business of Munich Re.
By NEXT Insurance · Via Business Wire · July 1, 2025
BILLERICA, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- E Ink (8069.TWO), the originator, pioneer, and global commercial leader in ePaper technology, announced the launch of a groundbreaking ePaper touchpad solution for laptops, developed through the integration of Intel® Smart Base, Intel® Innovation Platform Framework (Intel® IPF), and Intel® AI Assistant Builder technologies. This innovative solution combines color ePaper with traditional laptop touchpads, creating a visual, AI-assisted human-machine interface (HMI) that enhances user interaction and brings a whole new dimension of functionality to Intel-based AI PCs.
By E Ink · Via GlobeNewswire · July 1, 2025
PRINCETON, NJ / ACCESS Newswire / July 1, 2025 / In an increasingly digital and threat-prone world, Krishna's career journey-anchored in hands-on expertise and long-term vision-reflects the importance of resilience, adaptability, and purpose in cybersecurity. Raised and educated in India, Krishna's foundational years were marked not by shortcuts or quick wins, but by tireless curiosity and a passion for uncovering vulnerabilities that others overlooked.
Via ACCESS Newswire · July 1, 2025
YIWU, CHINA - Media OutReach Newswire - 1 July 2025 - China has launched its first railway container terminal with mixed-mode autonomous driving...
Via MediaOutReach · July 1, 2025
HARMAN International, a wholly owned subsidiary of Samsung Electronics Co., Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, today announced a multi-year partnership with ORBCOMM, a global leader in industrial IoT solutions, delivering visibility, intelligence and efficiency to some of the world’s largest shipping lines, over-the-road trucking, and cold-chain transportation fleets. This strategic partnership aims to further strengthen and expand ORBCOMM’s R&D operations by scaling innovation, delivering advanced data and platform engineering and global support for their asset intelligence product portfolio. ORBCOMM and HARMAN have come together to set up a new extended development center in Bangalore, one of the fastest-growing technology hubs in the world.
By HARMAN International · Via Business Wire · July 1, 2025
PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years to come. With expanding research and development efforts and a robust pipeline of novel medications, the neuropsychiatric disorders treatment landscape is evolving rapidly. Pharmaceutical companies are focusing on innovative drug therapies to meet the growing need for effective and affordable treatments. The market is primarily driven by the high incidence of mental illnesses, including depression and anxiety, and the rising awareness of these conditions. As a result, new treatment options are being developed, and drug-related activities such as clinical trials and drug approvals are intensifying. Recently an article on the 4th European Congress of Neurology and Neuropsychiatry website said that: “The global neuropsychiatric disorders and treatment market is on an upward trajectory, with a significant increase in demand for innovative solutions that cater to the growing burden of mental health conditions. In 2024, the market was valued at USD 130.5 billion, and by 2032, it is projected to reach USD 166.3 billion, growing at a compound annual growth rate (CAGR) of 10.20% from 2023 to 2032. This growth is fueled by continuous research, advancements in treatment, and heightened awareness of neuropsychiatric disorders.” Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Sage Therapeutics, Inc. (NASDAQ: SAGE), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), atai Life Sciences (NASDAQ: ATAI).
By FN Media Group LLC · Via GlobeNewswire · July 1, 2025
Moss, a top-ranked national construction management firm, announced today that Kim Henderson has been promoted to Chief Legal Officer, effective July 1, 2025. Henderson, who joined Moss in 2017, most recently served as Senior Vice President and General Counsel. She will continue to serve on the company’s Vision Leadership Team (VLT).
By Moss · Via Business Wire · July 1, 2025
New York, USA, 1st July 2025, Willkins, a next-generation health Read more
Via Zexprwire · July 1, 2025
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END
Via FinancialNewsMedia · July 1, 2025
Michael Boyd of Travis Buys Homes is pleased to announce that the company is prepared to work closely with property owners seeking a win-win solution to sell an unwanted, distressed, or unneeded property. The condition of the property doesn't matter; the buyers are ready to submit a fair cash offer and close quickly with no hassles and no hidden fees. The property can be in any condition, and there is no need to spend resources on repairs, inspections, renovations, or showings.
Via Get News · July 1, 2025
Adams County's award-winning library system, Anythink Libraries, is launching a groundbreaking collaboration with Adams County Poet Laureate and revered storyteller Kerrie Joy, featuring an immersive, interactive poetry experience within the library's virtual platform, Anythink World. This innovative partnership invites exploration, storytelling and creativity for all library cardholders through a deeply personal journey into Joy's creative process. The debut of this one-of-a-kind virtual poetry experience will kick off on July 15 with a unique in-person event at Anythink Wright Farms.
By Anythink Libraries · Via Business Wire · July 1, 2025